

## Case Studies Index

Locators in **bold** refer to tables; those in *italics* to figures

Broad classes/drug types are indexed below;  
 for specific drugs *see* drug index

Abnormal Involuntary Movement Scale (AIMS)  
 128

accommodation, SSRI-refractory anxiety 4

activation syndromes, SSRI-related 21, 29; *see*  
*also* mania (SSRI-induced)

clinical approaches 20

clinical reflections 25

family history 18

follow-ups (1st) 20

follow-ups (2nd) 22–23

medical history 18

medication 18, 19

medication mechanisms of action **26–28**,  
 27–29, 28

medication metabolism 22

medication pharmacogenetics 29–30

medication pharmacokinetics 23, 24

patient descriptions/evaluations 17, 19

post test self-assessment question 30–31

pretest self-assessment question 17

psychiatric history/evaluations 17, 19–20

psychotherapy history 18

social history 18–19

take-home points 25

test results 22

tips/pearls of wisdom 25–26

treatment-related weight gain 24

acute kidney injury 189

ADHD *see* attention deficit hyperactivity  
 disorder

adherence to medication 283, 283, 294–96  
 adolescence

sleep architecture 249–50

SSRI concentrations 182

adolescent case studies *see* anorexia nervosa;

anxiety; bipolar disorder; cannabis-  
 related drug interactions; insomnia

disorder; mania (SSRI-induced);  
 obsessive-compulsive disorder; SSRIs  
 (discontinuation); major depressive  
 disorder; schizophrenia

adrenergic uptake inhibitors *see*  $\alpha$ -adrenergic  
 agonists

adverse effects of medication 282

affective spectrum, SSRI-induced mania 70

age of onset, bipolar disorder 140

aggression, ASD in a child 259–60, 265, 273

akathisia 29, 58

alcohol use disorder 151

$\alpha$ -adrenergic agonists 229–30

ADHD in a child 111–15

concentration in relation to CYP2D6

metabolism 168

mechanisms of action 42–43, 254, 255

pharmacology/binding profile 166

plasma concentration–time curves 112

prefrontal cortex effects 167

PTSD with ADHD 41, 42

amygdala 9, 42, 42–43

anorexia nervosa, adolescent

clinical approaches 194, 196

family history 185

follow-ups (1st) 193–94

follow-ups (2nd) 194–95

follow-ups (3rd) 195–96

follow-ups (4th) 196

hospitalization 192–93

medical examinations in eating disorders  
**197**

medical history 185

medication 185

medication effects 200

medication mechanisms of action 198–99

medication plasma concentration–time  
 curves 199

patient descriptions/evaluations 185–86,  
 187–88, **190–92**

## Case Studies Index

- anorexia nervosa, adolescent (cont.)  
 post test self-assessment question 200–1  
 pretest self-assessment question 185  
 psychiatric history/evaluations 185, 189–90  
 psychotherapy history 185  
 refeeding syndrome risks **190**, 197–98  
 social history 185  
 take-home points 196–97  
 test results **188–89**, **193**, **195**  
 tips/pearls of wisdom 198
- anticholinergic symptoms  
 antipsychotics 295, 296–97  
 histamine antagonists 242  
 SSRIs 317–18, **318**  
 tricyclic antidepressants 86, 87, 89, 90
- antidepressant switching strategies **316**,  
 316–17; *see also* SSRIs; tricyclic  
 antidepressants
- antidiuretics 227–28  
 mechanisms of action **230**, **230**  
 sublingual formulation vs. tablets **229**
- antihistamines 241, **242**, **243**, **248**
- antihypertensives 95, 111–12, 115–16
- antipsychotics; *see also* second-generation  
 antipsychotics  
 mechanisms of action 132–33, 165  
 pharmacology/binding profile **133**, **166**
- anxiety in adolescence, SSRI tolerability/side  
 effects  
 antidepressant switching strategies **316**,  
 316–17  
 clinical approaches 304–5, **310**  
 clinical reflections 315  
 constipation 306  
 family history 301  
 follow-ups (1st and 2nd) 310  
 follow-ups (3rd) 311  
 follow-ups (4th) 312  
 mechanism-based inhibition **319**, 319–20  
 medical history 301  
 medication 301, 304, 310, 311  
 medication clearance relative to dosage **320**  
 medication mechanisms of action 317–18, **318**  
 medication serum concentrations **308**, **309**  
 patient descriptions/evaluations 301–2, 304  
 pharmacogenetic testing **306**  
 post test self-assessment question 321  
 pretest self-assessment question 301  
 psychiatric history/evaluations 301, 307–9  
 psychological testing 312–14  
 psychotherapy history 301  
 social history 301  
 take-home points 315–17  
 test results **305–6**
- anxiety in adolescence, treatment-resistant  
 clinical approaches 4–5  
 clinical reflections 8  
 family history 2  
 follow-ups (1st) 5  
 follow-ups (2nd) 6  
 follow-ups (3rd) 6–7  
 follow-ups (4th) 7  
 medical history 2, 3  
 medication 3  
 medication interactions 11, **12**, **13**  
 medication mechanisms of action 9, **10**, **11**  
 medication responses 9, 11, **12**  
 patient descriptions/evaluations 1, 3–4  
 post test self-assessment question 13–14  
 pretest self-assessment question 1  
 psychiatric history/evaluations 2, 4  
 psychotherapy history 3  
 social history 3  
 take-home points 7–8  
 tips/pearls of wisdom 9  
 ASD *see* autism spectrum disorder
- attention deficit hyperactivity disorder (ADHD),  
 child  
 clinical approaches 102, 105  
 developmental neurophysiology **108**,  
 108–10, **109**  
 educational history 96  
 family history 97  
 follow-ups (1st) 103–5  
 follow-ups (2nd) 105–6  
 follow-ups (3rd) 107  
 intelligence testing 97–99, **98**  
 medical history 97  
 medication 97, **102–3**  
 medication mechanisms of action **110**, 110–15  
 neuronal signal distribution **114**  
 neuropharmacology of ADHD **115**, **115**  
 patient descriptions/evaluations 95, 97, 102  
 plasma concentration–time curves 112  
 post test self-assessment question 115–16  
 pretest self-assessment question 95  
 psychiatric history/evaluations 96, 101  
 social history 97

- take-home points 107–8  
 test results 103, 104
- attention-deficit hyperactivity disorder, with  
 PTSD *see* posttraumatic stress disorder  
 combined with ADHD
- attention-deficit hyperactivity disorder, with tics  
*see* Tourette syndrome
- atypical antipsychotics *see* second-generation  
 antipsychotics
- autism spectrum disorder (ASD), side effects  
 of SGAs 276
- clinical approaches 264  
 clinical reflections 271  
 family history 259  
 follow-ups (1st) 265–66  
 follow-ups (2nd) 266  
 follow-ups (3rd) 267, 269–71  
 follow-ups (4th to 6th) 271  
 genetic work-up 275–76  
 medical history 259  
 medication 259, 261  
 medication effects on BMI 267  
 medication mechanisms of action 274–75  
 medication pharmacology/binding profile 270  
 medication responses 265  
 medication switching 273  
 patient descriptions/evaluations 259–60,  
 261–63  
 pharmacogenetic testing **268**, 272  
 post test self-assessment question 276  
 pretest self-assessment question 259  
 prolactin release 275  
 psychiatric history/evaluations 259, 264  
 psychotherapy history 259  
 Scales of Independent Behavior-Revised  
**262–63**  
 social history 259  
 take-home points 272  
 test results 267, **268–69**  
 tips/pearls of wisdom 273  
 Weschler Intelligence Scale for Children  
**261–62**, 262
- autoimmune disease **126**, 159
- avoidance, social anxiety disorder 3, 4, 8
- BEARS Sleep Screening Tool (B=Bedtime  
 Issues, E=Excessive Daytime Sleepiness,  
 A=Night Awakenings, R=Regularity and  
 Duration of Sleep, S=Snoring) **234–35**
- bedwetting *see* nocturnal enuresis
- benzodiazepines (BZDs)  
 benefits/response to 11  
 mechanisms of action 9, 10, 11  
 medication interactions 11, 12, 13  
 medication responses 12
- binding profiles *see* pharmacology/binding  
 profile
- bipolar disorder, medication dosage in  
 adolescents; *see also* mania (SSRI-  
 induced)  
 age of onset for diagnosis 140  
 BID vs. TID dosage regimes 151–52  
 clinical approaches 140, 142  
 family history 138  
 follow-ups (1st) 140–41  
 follow-ups (2nd) 142–46  
 illness details 149–51  
 lithium vs. placebo 146  
 medical history 138  
 medication 138, 139  
 medication mechanisms of action 148, 148–49  
 Monte Carlo simulations, concentration-dose  
 147  
 mood symptoms 150  
 patient descriptions/evaluations 137  
 pharmacokinetic clearance modeling 148  
 post test self-assessment question 152  
 pretest self-assessment question 137  
 psychiatric history/evaluations 137–38, 139  
 psychotherapy history 138  
 routine medication monitoring **144**, 146  
 social history 139  
 take-home points 146–47  
 test results **143**
- BMI (body mass index) *see* weight gain
- bowel function *see* constipation
- bullying 301
- BZDS *see* benzodiazepines
- caffeine exposure  
 insomnia disorder in an adolescent 239–40,  
 240  
 nocturnal enuresis in a child 225
- cannabis-related drug interactions  
 clinical approaches 208, 211, 212  
 clinical reflections 213  
 dopamine synthesis capacity in the striatum  
 210

## Case Studies Index

- caffeine exposure (cont.)  
 educational outcomes in cannabis users *210*  
 endogenous cannabinoid system *217, 217–19*  
 family history *203*  
 follow-ups (1st) *209–10*  
 follow-ups (2nd) *211*  
 follow-ups (3rd) *212*  
 medical history *203*  
 medication *203, 204*  
 medication effects *216*  
 medication mechanisms of action *215–17*  
 mesolimbic dopamine pathway *218*  
 monoamine/GABAergic/glutamatergic signaling *214*  
 N-acetylcysteine trial *213*  
 patient descriptions/evaluations *203, 205*  
 plasma concentration–time curves *206, 208*  
 post test self-assessment question *219–20*  
 pretest self-assessment question *203*  
 psychiatric history/evaluations *203, 205–8*  
 psychotherapy history *203*  
 social history *203*  
 take-home points *213–15*  
 THC effects **207**  
 THC exposure *207*  
 tips/pearls of wisdom *215*
- CBT *see* cognitive behavior therapy
- Child and Adolescent Service Intensity Instrument (CASII) *69*
- Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS) *79, 80–81*
- child case studies *see* activation syndromes;  
 attention-deficit hyperactivity disorder;  
 autism spectrum disorder; nocturnal enuresis;  
 posttraumatic stress disorder;  
 Tourette syndrome
- children  
 sleep architecture *249*  
 SSRI concentrations *182*
- circadian rhythms  
 in depression *239*; *see also* insomnia disorder  
 diurnal variation in urine production *231*  
 medication mechanisms of action *251, 251–52*
- CNS (central nervous system) stimulants; *see also*  $\alpha$ -adrenergic agonists  
 mechanisms of action *110, 110–15, 114*  
 neuropharmacology *115*
- cognitive behavior therapy (CBT)  
 insomnia disorder in an adolescent *241*  
 SSRI discontinuation in adolescents *181*
- complete blood count, SSRI side effects **305–6**
- compliance with medication *283, 283, 294–96*
- constipation  
 SGAs **296**  
 SSRIs *306*
- Coping Cat* psychotherapy intervention *19*
- cortisol dynamics, ADHD with PTSD *44*
- COVID-19 pandemic *233*
- cyclic adenosine monophosphate (cAMP) *114, 115, 115*
- CYP2C19 (cytochrome P450 2C19) metabolism  
 drug clearance *25–26, 26*  
 effects of SSRIs *21, 22, 29–30*
- CYP2D6 (cytochrome P450 2D6) metabolism  
 MDD *59, 60*  
 Tourette syndrome *168*
- delusions *122, 127, 279–80*
- depression *66*; *see also* major depressive disorder  
 sleep/wake cycles *239*
- developmental milestones, delayed autism spectrum disorder *259*  
 early-onset schizophrenia *121*  
 Tourette syndrome *155*
- developmental neurophysiology, ADHD *108–10*  
 brain circuits *109*  
 brain maturation/onset of psychiatric disorders *108*
- diagnostic criteria *see* DSM-5 criteria
- disinhibition *259*
- dopamine/dopaminergic system  
 cannabis-related drug interactions *210*  
 CNS stimulants *110, 114*  
 effects of caffeine exposure *240*  
 reward systems *218*  
 side effects of SGAs *275*
- dopamine–serotonin receptor antagonists *see* second-generation antipsychotics
- DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria  
 ADHD *35, 223*  
 anorexia nervosa *189*  
 bipolar disorder *149*  
 major depressive disorder *49, 203*

- nocturnal enuresis 225  
 sleep disorder 160  
 Tourette syndrome 163  
 drugs *see* medication
- early-onset schizophrenia, adolescence  
 clinical approaches 122, 126, 128, **129**  
 family history 121  
 follow-ups (1st) 123  
 follow-ups (2nd) 126–28, **128**  
 follow-ups (3rd) 128–30, **129**  
 follow-ups (4th) 131  
 medical history 120–21  
 medication mechanisms of action 132–33  
 medication pharmacology/binding profile 133  
 patient descriptions/evaluations 119, 121–22  
 post test self-assessment question 134  
 pretest self-assessment question 119  
 psychiatric history/evaluations 120, 122  
 psychotherapy history 120  
 social history 121  
 take-home points 132  
 test results 123–24, **124–25**, **126**, **128**
- eating disorders *see* anorexia nervosa
- educational history, ADHD in a child 96
- educational outcomes, cannabis users 210
- endocannabinoid system 217, 217–19
- enuresis *see* nocturnal enuresis
- Epworth sleepiness scale **237**
- exposure work, child and adolescent anxiety 6
- extrapyramidal symptoms (EPS) 127–28, 132
- Family-to-Family Program (National Alliance on Mental Illness) 279
- family-based therapy 185, 193
- family history *see under specific cases*
- 5-HT *see* serotonin
- Fluid Reasoning Index (FRI), WISC-5 99
- fragile X syndrome 259, 264, 272
- GABA<sub>A</sub> (gamma aminobutyric acid sub-type A) receptors 9, 10
- GABAergic signaling, drug interactions 214
- General Ability Index (GAI), WISC-5 97–99
- generalized anxiety disorder (GAD) 3, 4, 13, 19, 61; *see also* anxiety
- genetics *see* pharmacogenetics
- glutamatergic signaling, drug interactions 214
- hallucinations 122, 127, 279
- headaches 138, 228, 267, 301
- herbal supplements 126
- hippocampus atrophy, ADHD with PTSD 45
- histamine 1 receptor antagonists 241, 242, 243, 248
- hyperbolic discontinuation, SSRIs 180
- hypotension 298
- hypothalamic pituitary adrenal (HPA) axis 45
- individualized education plans (IEPs) 72, 259
- infections, Tourette syndrome 158
- insomnia 35–36; *see also* posttraumatic stress disorder
- insomnia disorder, adolescence 233  
 BEARS Sleep Screening Tool **234–35**  
 caffeine exposure 239–40, 240  
 circadian rhythms, effect of depression 239  
 clinical approaches 241, 244, 246  
 Epworth Sleepiness Scale **237**  
 family history 233  
 follow-ups (1st) 241–42  
 follow-ups (2nd) 243–44  
 follow-ups (3rd) 244–45  
 follow-ups (4th) 245–46  
 follow-ups (5th) 247  
 medical history 233  
 medication 233, 242, 243  
 medication mechanisms of action 251, 251–52, 254, 255  
 patient descriptions/evaluations 233, 236–37  
 post test self-assessment question 256  
 pretest self-assessment question 233  
 psychiatric history/evaluations 233–34, 238–41  
 psychotherapy history 233  
 sleep architecture in adolescence 249–50  
 sleep architecture in childhood 249  
 social history 233  
 social jet lag 239  
 take-home points 248–49  
 test results **237–38**, 246–47  
 tips/pearls of wisdom 250
- intelligence testing, ADHD 97–99, **98**
- intellectual disability 259, 264, 276
- interpersonal psychotherapy (IPT) 38, 54, 65–66, 120, 196, 311
- iron studies, insomnia disorder **238**, **247**

## Case Studies Index

- kidney disease 151, 279
- laboratory tests *see under specific cases* (test results)
- major depressive disorder (MDD), treatment  
 resistant  
 clinical approaches 54, 57  
 CYP2D6 phenotype 59, 60  
 family history 49  
 follow-ups (1st) 54–55  
 follow-ups (2nd) 55–58  
 follow-ups (3rd) 58  
 medical history 49  
 medication 49, 50  
 medication plasma concentration–time curves 60  
 patient descriptions/evaluations 49, 51–53  
 phenoconversion 59  
 post test self-assessment question 60–61  
 pretest self-assessment question 49  
 psychiatric history/evaluations 49, 54  
 psychotherapy history 49  
 social history 49  
 take-home points 58–59  
 tips/pearls of wisdom 59
- mania, SSRI-induced 69; *see also* activation syndromes; bipolar disorder  
 affective spectrum/mood disorders continuum 70  
 clinical approaches 68  
 family history 66  
 follow-ups (1st) 67–68  
 follow-ups (2nd) 68–70  
 follow-ups (3rd) 71–72  
 medical history 66  
 medication 66, 71–72, 73–74  
 medication mechanisms of action 74  
 medication pharmacology/binding profile 75  
 medication plasma concentration time curves 73  
 patient descriptions/evaluations 65–67  
 post test self-assessment question 75  
 pretest self-assessment question 65  
 psychiatric history/evaluations 66, 67  
 psychotherapy history 66  
 social history 66  
 take-home points 72–73  
 tips/pearls of wisdom 73–74
- MDD *see* major depressive disorder  
 mechanism-based inhibition, SSRIs 319, 319–20  
 medication dosage *see* bipolar disorder (medication dosage)  
 medication interactions *see* cannabis-related interactions  
 medication side effects *see* side effects  
 medication withdrawal *see* SSRIs, discontinuation  
 mesolimbic dopamine pathway, reward systems 218  
 methyl tetrahydrofolate reductase (*MTHFR*) gene 284  
 mindfulness-based therapies 138  
 mixed dopamine–serotonin receptor antagonists *see* second-generation antipsychotics  
 mixed symptoms, mood disorders continuum 70  
 monoamine signaling, drug interactions 214; *see also* dopamine; norepinephrine; serotonin  
 Monte Carlo simulations, drug concentrations 147; *see also* bipolar disorder (medication dosage)  
 mood disorders continuum, SSRI-induced mania 70  
 mood stabilizers 138, 139; *see also* bipolar disorder (medication dosage)  
 mechanisms of action 148, 148–49  
 pharmacokinetics 147  
 movement disorders 29, 58, 246, 247  
 movement ratings, early-onset schizophrenia 129  
 MRI scanning, early-onset schizophrenia 123–24  
*MTHFR* (methyl tetrahydrofolate reductase) gene 284
- National Alliance on Mental Illness (NAMI) 279  
 nausea 3, 41, 138, 203  
 NDRI *see* norepinephrine–dopamine reuptake inhibitors  
 neuronal signal distribution, ADHD in a child 114  
 neutropenia 294–95  
 nocturnal enuresis, child 230  
 caffeine exposure 225  
 clinical approaches 225

- diurnal variation in urine production *231*  
 family history *224*  
 follow-ups (1st) *226*  
 medical history *224*  
 medication *224*  
 medication effects *229*  
 medication mechanisms of action *230, 230*  
 medication responses **226**  
 patient descriptions/evaluations *223, 224–25*  
 post test self-assessment question *231*  
 pretest self-assessment question *223*  
 psychiatric history/evaluations *223, 225*  
 social history *224*  
 take-home points *227*  
 tips/pearls of wisdom *227–30*
- non-adherence *see* adherence to medication  
 norepinephrine; *see also* SNRIs  
 CNS stimulants *110, 114, 115*  
 PTSD with ADHD *42, 43–45, 44*  
 receptors *253*
- norepinephrine–dopamine reuptake inhibitors (NDRIs)  
 effects on prefrontal cortex and striatum *216*  
 mechanisms of action *215–17*
- obsessive-compulsive disorder, adolescence  
 clinical approaches *82–83, 85–86*  
 family history *78, 82*  
 follow-ups (1st) *83–84*  
 follow-ups (2nd) *85–86*  
 follow-ups (3rd) *87–88*  
 medical history *78*  
 medication *78, 79, 85*  
 medication mechanisms of action *89–90*  
 medication receptor pharmacology *90*  
 medication responses *91*  
 patient descriptions/evaluations *77–78, 79, 80–81*  
 post test self-assessment question *91*  
 pretest self-assessment question *77*  
 psychiatric history/evaluations *78, 81–82*  
 psychotherapy history *78*  
 social history *78*  
 take-home points *88–89, 89*  
 test results *84, 86*  
 tips/pearls of wisdom *90*  
 treatment outcomes *82*
- omega-3 fatty acid supplementation  
 bipolar disorder *67*  
 schizophrenia *122, 126, 127, 131*  
 SSRI-induced mania *72*
- opioid antagonists  
 effects on ventral tegmental area *200*  
 mechanisms of action *198–99*  
 plasma concentration–time curves *199*
- oral contraceptives *138, 301, 302*  
 orthostatic hypotension *298*
- Patient Health Questionnaire-9 (PHQ-9) *51–52*  
 pediatrics *see* adolescent case studies; child case studies
- Personality Assessment Inventory for Adolescents (PAI-A) *53*
- pharmacogenetics  
 SGAs **268, 272**  
 SSRIs *29–30, 306*
- pharmacokinetics  
 mood stabilizers *148*  
 SSRIs *23, 24, 26, 179, 320, 321*
- pharmacology/binding profiles  
 $\alpha$ -adrenergic agonists *166*  
 antipsychotics *133, 166*  
 NDRIs *166*  
 SGAs *74, 270, 297*
- phenoconversion *59*  
 plasma concentration–time curves  
 $\alpha$ -adrenergic agonists *112*  
 opioid antagonists *199*  
 SGAs *73*  
 SSRIs *206, 208*
- polycystic ovarian syndrome *75*  
 posttraumatic stress disorder (PTSD)  
 combined with ADHD  
 clinical approaches *38*  
 family history *37*  
 follow-ups (1st) *38–39*  
 follow-ups (2nd) *39–40*  
 follow-ups (3rd) *40*  
 HPA axis stress response *45*  
 medical history *36, 37*  
 medication *36, 37*  
 medication mechanism of action *42–43*  
 medication responses *42*  
 noradrenergic hyperactivity *42*  
 norepinephrine and cortisol dynamics *43–45, 44*  
 patient descriptions/evaluations *35, 37*  
 post test self-assessment question *45*

## Case Studies Index

- posttraumatic stress disorder (PTSD)  
 combined with ADHD (cont.)  
 pretest self-assessment question 35  
 psychiatric history/evaluations 35–36, 37  
 psychotherapy history 37  
 social history 37  
 take-home points 40–41  
 tips/pearls of wisdom 41  
 PRACTICE acronym, PTSD 38–39  
 prefrontal cortex  
 $\alpha$ -adrenergic agonists 167  
 norepinephrine–dopamine reuptake inhibitors 216  
 Processing Speed Index (PSI), WISC-5 99  
 prolactin release, side effects of SGAs 275  
 psychosis *see* early-onset schizophrenia; schizophrenia  
 psychotherapy *see under specific cases*  
 PTSD *see* posttraumatic stress disorder
- Quick Inventory of Depressive Symptoms (QUIDS -SR) 51–52
- receiver operating characteristic (ROC) curves, SGAs 291
- re-feeding syndrome **190**, 197–98; *see also* anorexia nervosa
- relapses 181; *see also* SSRI discontinuation
- renal disease 151, 279
- reward systems, mesolimbic dopamine pathway 218
- safety concerns *see* suicidal ideation
- Scales of Independent Behavior-Revised (SIB-R) **262–63**
- schizophrenia, treatment-resistant; *see also* early-onset schizophrenia  
 clinical approaches 284, 285, 289  
 clinical reflections 294  
 constipation **296**  
 family history 279  
 follow-ups (1st) 285–87  
 follow-ups (2nd to 4th) 287–88  
 follow-ups (5th) 288–89  
 follow-ups (6th) 289–91  
 follow-ups (7th) 291–94  
 medical history 279  
 medication 279, 281, 287, 288, 293  
 medication adherence 283, 294–96  
 medication checklist for initiation **286**  
 medication dosage relative to serum concentration 289, 298  
 medication mechanisms of action 296–98  
 medication outpatient titration values **286**  
 medication pharmacology/binding profile 297  
 medication responses 291  
 medication responses and adverse effects 282  
 patient descriptions/evaluations 279–80, 282  
 post test self-assessment question 298  
 pretest self-assessment question 279  
 psychiatric history/evaluations 279, 282–83  
 psychotherapy history 279  
 social history 279  
 take-home points 294–96  
 test results **284–85**, **290**, **292–93**
- second-generation antipsychotics (SGAs); *see also* autism spectrum disorder (side-effects of SGAs)  
 adherence to medication 283, 294–96  
 adverse effects 282  
 checklist for initiation **286**  
 constipation **296**  
 CYP2D6 phenotype 59  
 dosage relative to serum concentration 289, 298  
 mechanisms of action 74, 274–75, 275, 296–98  
 outpatient titration values **286**  
 pharmacology/binding profile 74, 270, 297  
 plasma concentration–time curves 60  
 receiver operating characteristic curves 291  
 SSRI-induced mania 71–72, 73–74
- sedation (side effect) 3, 6, 23, 69–70, 133, 166, 296, 317
- sedatives *see* benzodiazepines
- selective serotonin reuptake inhibitors *see* SSRIs
- serotonin–norepinephrine reuptake inhibitors (SNRIs) 9
- separation anxiety 9
- serotonin, effects of SGAs 275; *see also* SSRIs
- sexual dysfunction 317, 318
- SGAs  
*see* second-generation antipsychotics
- side effects of medication; *see also* activation syndromes; anxiety in adolescence;



- autism spectrum disorder; mania; sedation; weight-gain
- SGAs *267, 275, 296*
- SSRIs *306*
- sleep architecture; *see also* insomnia disorder
  - adolescence *249–50*
  - childhood *249*
  - sleep disorders *160*; *see also* insomnia disorder
  - sleep hygiene *39*
  - SNRIs (serotonin–norepinephrine reuptake inhibitors) *9*
  - social anxiety disorder *1, 3, 4, 8, 9, 185, 301, 307–9*
  - social jet lag *239*; *see also* insomnia disorder
  - socioeconomic status *151*
  - somatodendritic  $\alpha$ -2 receptors *255*
  - SSRIs (selective serotonin reuptake inhibitors) *177–78*; *see also* activation syndromes; anxiety; cannabis-related drug interactions; mania (SSRI-induced)
    - concentrations in children and adolescents *182*
    - CYP2C19 metabolism *24, 176*
    - CYP2D6 phenotype *59*
    - mechanism-based inhibition *319, 319–20*
    - mechanisms of action **26–28, 27–29, 28, 181, 317–18**
    - metabolism *22*
    - pharmacogenetics *29–30, 306*
    - pharmacokinetics *23, 24, 26, 320, 321*
    - plasma concentration–time curves *24, 176, 177, 206, 208*
    - PTSD with ADHD *39*
    - responses to *9, 91*
    - serum concentrations *308, 309*
    - weight gain, treatment-related *24*
    - withdrawal pharmacokinetics/ pharmacodynamics *179*; *see also below*
- SSRIs, discontinuation in adolescents
  - clinical approaches *177*
  - CYP2C19 metabolism *176*
  - family history *174*
  - follow-ups *177–78*
  - medical history *174*
  - medication *174*
  - medication concentrations in children and adolescents *182*
  - medication mechanisms of action *181*
  - medication plasma concentration–time curves *176, 177*
  - patient descriptions/evaluations *173, 174*
  - post test self-assessment question *183*
  - pretest self-assessment question *173*
  - psychiatric history/evaluations *173–74, 175*
  - psychotherapy history *174*
  - relapses *181*
  - social history *174*
  - take-home points *178–79*
  - test results *175*
  - tips/pearls of wisdom *180*
  - withdrawal pharmacokinetics/ pharmacodynamics *179*
- stimulants *see* CNS (central nervous system) stimulants
- stress response *45*; *see also* posttraumatic stress disorder
- striatum
  - cannabis-related drug interactions *210*
  - norepinephrine–dopamine reuptake inhibitors *216*
  - substance abuse *see* cannabis-related drug interactions
- suicidal ideation
  - anorexia nervosa *185, 198*
  - bipolar disorder *138*
  - early-onset schizophrenia *121–22*
- therapeutic drug monitoring **86, 90, 147, 182, 295–96**
- Tourette syndrome, child
  - clinical approaches *160*
  - CYP2D6 metabolism *168*
  - developmental milestones *155*
  - family history *155*
  - follow-ups (1st) *160–61*
  - follow-ups (2nd) *161–62*
  - follow-ups (3rd) *162–63*
  - follow-ups (4th) *163*
  - medical history *155*
  - medication *155, 157, 161*
  - medication effects *167*
  - medication mechanisms of action *165–67*
  - medication pharmacology/binding profile *166*
  - parental resources *169*
  - patient descriptions/evaluations *155, 157–58*
  - post test self-assessment question *168*

## Case Studies Index

- Tourette syndrome, child (cont.)  
 pretest self-assessment question 155  
 psychiatric history/evaluations 155, 159–60  
 psychotherapy history 155  
 rating scales **158–59**, 158, **163**  
 take-home points 163–64  
 test results 162  
 tips/pearls of wisdom 165
- Tourette's Impairment – Child self report  
**158–59**, 158, **163**
- transcranial magnetic stimulation (TMS) 4–5
- trauma *see* posttraumatic stress disorder
- treatment-resistant anxiety *see* anxiety
- treatment-resistant depression *see* major depressive disorder
- treatment-resistant schizophrenia *see* schizophrenia
- tricyclic antidepressants  
 mechanisms of action 89–90  
 metabolism of 88  
 receptor pharmacology 90  
 therapeutic drug monitoring **86**; *see also* obsessive compulsive disorder
- urine production, diurnal variation 231; *see also* nocturnal enuresis
- Vanderbilt ADHD Rating Scale 99
- vasodilators, mechanisms of action 252, 254
- ventral tegmental area (VTA), opioid antagonists 200
- Verbal Comprehension Index (VCI), WISC-5 98
- vesicular monoamine transporter 2 (VMAT2) 253
- Visual-Spatial Index (VSI), WISC-5 99
- vitamin D deficiency **190–92**
- weight gain, treatment-related 23, 24, 267; *see also* autism spectrum disorder (side effects of SGAs)
- weight loss 7, 51, 105, **190**, 194; *see also* anorexia nervosa
- Weschler Intelligence Scale for Children (WISC-V) 97–99, **261–62**
- withdrawal from medication *see* SSRIs (discontinuation)
- Working Memory Index (WMI), WISC-5 99

## Drugs Index

Locators in **bold** refer to tables; those in *italics* to figures

- Abilify *see* aripiprazole  
 acetaminophen 138, 139  
 acetylcysteine 212, 213–15, **213**  
 Adderall *see* amphetamine salts  
 Adnasia XR *see* methylphenidate  
 albuterol 279  
 amitriptyline 224  
 amphetamine salts 105–6, 155, 168, 264  
 Anafranil *see* clomipramine  
 Aptensio XR *see* methylphenidate  
 arginine vasopressin (AVP) 229–30  
 aripiprazole 20, 57, 59, **60**, 70, 77, 91, 121,  
 128, 137, 139, 140–41, 150, 155, 160–61,  
 162–64, 168, 203, 213–15, 219–20, 259,  
 269–74, 276, 279, 310  
 armodafinil 85–86  
 asenapine 65, 68–70, 71–72, 73–74, 75, 150,  
 285  
*ashwagandha* 126  
 atomoxetine 102, 155, 157, 160–61, 162–63,  
 166–68, 211–12  
 atorvastatin 121  
 Azstarys *see* serdexmethylphenidate
- benztropine 128, 296–97  
 bisacodyl 295  
 bromocriptine 269–71  
 bupropion 3–4, 208, 211–12, 215–17
- carbamazepine 65, 75, 150  
 Catapres *see* clonidine  
 cetirizine 2, 3  
 chloral hydrate 241  
 chlorpromazine 296–97  
 ciprofloxacin 293  
 citalopram 22–23, 29–30, 38–45, 213–15,  
 219–20  
 clomipramine 77, 83, 84–87, 89–90, 91, 310  
 clonazepam 13–14, 20
- clonidine 18, 19, 42–43, 107–8, 110–15,  
 160–63, 233–34, 241–42, 250, 259, 261  
 clozapine 65, 75, 119, 121, 279, 284–98  
 Clozaril *see* clozapine  
 Colace *see* docusate  
 Concerta *see* methylphenidate (OROS  
 formulation)  
 Contempla XR *see* methylphenidate  
 Cozaar *see* losartan  
 Crestor *see* rosuvastatin  
 Cymbalta *see* duloxetine  
 cyproheptadine 194
- Daytrana *see* methylphenidate  
 DDAVP *see* desmopressin  
 Depakote *see* divalproex  
 Desaryl *see* trazodone  
 desmethylclomipramine *see* norclomipramine  
 desmopressin 223, 225–26, 227–30, **230**,  
 231  
 desvenlafaxine 223, 231  
 dexmethylphenidate 36, 37, **102–3**  
 diazepam 155, 168  
 diphenhydramine 241–42, 243–44, 250  
 divalproex 3, 65, 67, 75, 138, 150  
 docusate 85–86, 293–95, 301, 304, 310  
 drospirenone 139  
 duloxetine 1, 4–5, 13–14, 20, 49, 60–61, 77,  
 91, 105–6
- Effexor *see* venlafaxine  
 Emsan *see* selegeline  
 escitalopram 13–14, 20, 22–23, 24, 25–26,  
 29–30, 49, 57, 126, 137–38, 142, 178–79,  
 213–15, 219–20, 269–71, 301, 307–8,  
 321  
 ethinyl estradiol 139
- fexofenadine 66

## Drugs Index

- fluoxetine 3–4, 39, 49, 54–61, 67–70, 78, 88, 120, 150, 179, 180, 183, 185, 194, 203, 213–15, 219–20, 223, 231, 233–34, 241, 243–46, 285, 310–11, 315–17  
 fluvoxamine 78, 79, 82–83, 88, 301, 321  
 Focalin *see* dexmethylphenidate
- Glucophage XR *see* metformin  
 guanfacine 1, 13–14, 17, 30–31, 38, 42–43, 102, 105–6, 107–8, 110–15, 264
- Haldol *see* haloperidol  
 haloperidol 119, 160–61, 164  
 hydroxyzine 18, 19, 20, 301–2, 304, 310–11
- iloperidone 273  
 imipramine 39, 77, 91, 223, 225–26, 227, 231  
 Inderal *see* propranolol  
 Intuniv *see* guanfacine  
 Invega *see* paliperidone
- Jornay *see* methylphenidate
- Kapvay *see* clonidine  
 Klonopin *see* clonazepam
- lactulose 295  
 lamotrigine 150  
 Lexapro *see* escitalopram  
 lithium 137, 140–41, 142, **143**, 143–149, 151–52  
 loratadine 97  
 losartan 279  
 lurasidone 70, 150, 165, 273  
 Luvox *see* fluvoxamine
- melatonin 18, 36, 37, 38, 39, 45, 49, 50, 54, 155, 157, 233, 244–46, 248, 251–52, 256, 259, 264  
 MetadateCD *see* methylphenidate  
 Metamucil *see* psyllium fiber supplement  
 metformin 66, 72, 121, **129**, 130, 132, 279  
 methylphenidate 91, 97, 99, 102, **102–3**, 103–6, 107–8, 110–15  
 methylphenidate (OROS formulation) 101, 155, 168, 259  
 Minipress *see* prazosin  
 Miralax *see* polyethylene glycol  
 mirtazapine 241, 244–46, 250
- Moban *see* molindone  
 molindone 119
- N-acetylcysteine (NAC) 122, 212, 213–15, 213  
 naltrexone 185, 196, 198–99, 200–1, 200, 208  
 norclomipramine 85–87, 89  
 norgestimate-ethinyl estradiol 304, 310–11
- olanzapine 150, 185, 193–96, 200–1  
 OrthoLo *see* norgestimate-ethinyl estradiol  
 oxcarbazepine 150  
 oxytocin 233, 256
- paliperidone 119, 126–28, 131, 132–33, 259, 269–71, 273, 276, 285  
 paroxetine 35, 45, 49, 60–61, 185, 194, 200–1, 211–12, 301–2, 304–5, 308, 310–11, 315–21  
 Paxil *see* paroxetine  
 perphenazine 126  
 pimozone 164  
 polyethylene glycol 293–95  
 prazosin 35, 38–45  
 Pristiq *see* desvenlafaxine  
 propranolol 35, 45  
 Prozac *see* fluoxetine  
 psyllium fiber supplement 301, 304, 310
- quetiapine 3, 35, 45, 66, 67, 68, 150, 279  
 Quillichew *see* methylphenidate  
 Quillivant *see* methylphenidate
- ramelteon 233, 256  
 Revia *see* naltrexone  
 Risperdal *see* risperidone  
 risperidone 82–83, 132–33, 150, 259, 264–65, 269–74, 276, 279, 280–82, 284–86  
 Ritalin LA *see* methylphenidate  
 rosuvastatin 279
- Saphris *see* asenapine  
 selegiline 185, 200–1  
 sennosides 295  
 serdexmethylphenidate **102–3**  
 Seroquel *see* quetiapine  
 sertraline 3, 5, 8, 22–23, 29–30, 38, 39, 88, 174–79, 181, 182, 203, 205–6, 208, 209–10, 211–12, 213–15, 219–20, 301, 321

Strattera *see* atomoxetine  
suvorexant 233, 244–46, 256

Tegratol *see* carbamazepine  
Tenex *see* guanfacine  
THC (tetrahydrocannabinol) 207, **207**  
Tofranil *see* imipramine  
topiramate **129**, 130  
trazodone 54, 55, 243–44, 250  
Trintellix *see* vortioxetine

Valium *see* diazepam  
venlafaxine 49, 54, 60–61, 77, 91

Viiibryd *see* vilazodone  
vilazodone 203, 219–20, 301, 321  
viloxazine 224, 225, 229–30  
Vistaril *see* hydroxyzine  
vortioxetine 259, 276

Wellbutrin *see* bupropion

ziprasidone 165, 273  
Zoloft *see* sertraline  
zolpidem 241, 244–46, 249  
Zyprexa *see* olanzapine  
Zyrtec *see* cetirizine